PE20040764A1 - INDAZOLE DERIVATIVES AS ANTAGONISTS OF CORTICOTROPIN RELEASE FACTOR (CRF) - Google Patents
INDAZOLE DERIVATIVES AS ANTAGONISTS OF CORTICOTROPIN RELEASE FACTOR (CRF)Info
- Publication number
- PE20040764A1 PE20040764A1 PE2003001215A PE2003001215A PE20040764A1 PE 20040764 A1 PE20040764 A1 PE 20040764A1 PE 2003001215 A PE2003001215 A PE 2003001215A PE 2003001215 A PE2003001215 A PE 2003001215A PE 20040764 A1 PE20040764 A1 PE 20040764A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- indazole
- alcoxy
- nrarb
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
SE REFIERE A DERIVADOS DE INDAZOL DE FORMULA I O II, EN DONDE R2 ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C6), (CICLOALQUIL(C3-C6)-ALQUILO(C1-C3), (ALQUIL(C1-C6))CARBONILO, ALQUILSULFONILO(C1-C6), ARILO O ARILALQUILO QUE ESTAN EVENTUALMENTE SUSTITUIDOS POR ALQUILO(C1-C6), HALOALQUILO, ALCOXI (C1-C6) Y HALOGENO; R3 ES ARILO O HETEROARILO, EVENTUALMENTE SUSTITUIDOS POR DE ALQUILO(C1-C6), ALCOXI(C1-C6), ALQUILTIO(C1-C6), ALQUILSULFONILO(C1-C6), ENTRE OTROS; R1 EN EL CASO DE LA FORMULA I, ES -NRaRb, -CRcRdRe, CO2Ra o C(O)NRaRb; EN EL CASO DE LA FORMULA II ES NRaRb, CrcRdRe, CO2Ra; O EN EL CASO DE LAS FORMULAS I O II ES H, CICLOALQUENILO, ARILO O HETEROARILOQUE ESTAN EVENTUALMENTE SUSTITUIDOS POR ALQUILO(C1-C6), ALCOXI(C1-C6), ALQUILTIO(C1-C6), ALQUILSULFONILO(C1-C6), HALOGENO, ENTRE OTROS; Ra Y Rb SON H, ALQUILO(C1-C9), HIDROXIALQUILO, (ALCOXI C1-C6)-ALQUILO, ENTRE OTROS; O JUNTOS CON EL N FORMAN UN ANILLO HETEROCICLILO O HETEROARILO. SON COMPUESTOS PREFERIDOS: EL CLORHIDRATO DEL 7-(2,4-DICLORO-FENIL)-2-METIL-3-(1-PROPIL-BUT-1-ENIL)-2H-INDAZOL, CLORHIDRATO DE 2-METIL-3-(1-PROPIL-BUT-1-ENIL)-7-(2,4,6-TRIMETIL-FENIL)-2H-INDAZOL, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON ANTAGONISTAS DE RECEPTORES DEL FACTOR CRF Y PUEDEN USARSE PARA EL TRATAMIENTO DE TRANSTORNOS SIQUIATRICOS Y ENERMEDADES NEUROLOGICAS COMO LAS RELACIONADAS CON EL ESTRES, TRASTORNOS DE ANIMO, DE ALIMENTACION, DE ANSIEDAD, DISFUNCIONES GASTROINTESTINALES INDUCIDAS POR ESTRESREFERS TO INDAZOLE DERIVATIVES OF FORMULA IO II, WHERE R2 IS H, ALKYL (C1-C6), CYCLOALKYL (C3-C6), (CYCLOALKYL (C3-C6) -ALKYL (C1-C3), (ALKYL (C1 -C6)) CARBONYL, ALKYLSULPHONYL (C1-C6), ARYL OR ARYLALKYL WHICH ARE EVENTUALLY REPLACED BY ALKYL (C1-C6), HALOALKYL, ALCOXY (C1-C6) AND HALOGEN; EVENTUALLY IS ARYL OR HALOGENE ALKYL, EVENTUALLY SUBSTITUTED BY ALKYL (C1-C6), ALCOXY (C1-C6), ALKYLTIO (C1-C6), ALKYLSULFONILO (C1-C6), AMONG OTHERS; R1 IN THE CASE OF FORMULA I, IS -NRaRb, -CRcRdRe, CO2Ra or C ( O) NRaRb; IN THE CASE OF FORMULA II IT IS NRaRb, CrcRdRe, CO2Ra; OR IN THE CASE OF FORMULAS I OR II IT IS H, CYCLOALKENYL, ARYL OR HETEROARYL, WHICH ARE EVENTUALLY REPLACED BY ALKYL, (C1-C6) C6), ALKYLTIO (C1-C6), ALKYLSULFONYL (C1-C6), HALOGEN, AMONG OTHERS; Ra AND Rb ARE H, ALKYL (C1-C9), HYDROXYALKYL, (C1-C6 ALCOXY) -ALKYL, AMONG OTHERS; OR TOGETHER WITH N, THEY FORM A HETEROCYCLYL OR HETEROARYL RING.THE PREFERRED COMPOUNDS ARE: 7- (2,4-DICLO HYDROCHLORIDE RO-PHENYL) -2-METHYL-3- (1-PROPYL-BUT-1-ENYL) -2H-INDAZOLE, 2-METHYL-3- (1-PROPYL-BUT-1-ENYL) -7- ( 2,4,6-TRIMETHYL-PHENYL) -2H-INDAZOLE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THESE COMPOUNDS ARE ANTAGONISTS OF RECEPTORS OF THE CRF FACTOR AND MAY BE USED FOR THE TREATMENT OF PSYCHIATRIC DISORDERS AND NEUROLOGICAL DISEASES SUCH AS THOSE RELATED TO STRESS, ANIMAL DISORDERS, EATING DISORDERS, ANXIETY, GASTROINTESTONE, DYSFUNCTION
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43016802P | 2002-12-02 | 2002-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040764A1 true PE20040764A1 (en) | 2004-11-06 |
Family
ID=32469420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003001215A PE20040764A1 (en) | 2002-12-02 | 2003-11-28 | INDAZOLE DERIVATIVES AS ANTAGONISTS OF CORTICOTROPIN RELEASE FACTOR (CRF) |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7214699B2 (en) |
| EP (1) | EP1569911B1 (en) |
| JP (1) | JP4401298B2 (en) |
| KR (1) | KR100761562B1 (en) |
| CN (1) | CN100439341C (en) |
| AR (1) | AR042148A1 (en) |
| AT (1) | ATE399768T1 (en) |
| AU (1) | AU2003286180B2 (en) |
| BR (1) | BR0316950A (en) |
| CA (1) | CA2507074A1 (en) |
| DE (1) | DE60321958D1 (en) |
| ES (1) | ES2309368T3 (en) |
| GT (1) | GT200300263A (en) |
| MX (1) | MXPA05005794A (en) |
| PA (1) | PA8589601A1 (en) |
| PE (1) | PE20040764A1 (en) |
| PL (1) | PL377609A1 (en) |
| RU (1) | RU2341518C2 (en) |
| TW (1) | TW200418816A (en) |
| UY (1) | UY28105A1 (en) |
| WO (1) | WO2004050634A1 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| RU2376292C2 (en) * | 2003-08-14 | 2009-12-20 | Ф.Хоффманн-Ля Рош Аг | Gaba-ergic modulators |
| US6984652B2 (en) * | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
| GB0400895D0 (en) * | 2004-01-15 | 2004-02-18 | Smithkline Beecham Corp | Chemical compounds |
| TW200616967A (en) * | 2004-06-24 | 2006-06-01 | Smithkline Beecham Corp | Novel indazole carboxamides and their use |
| MX2007000791A (en) * | 2004-08-03 | 2007-03-23 | Wyeth Corp | Indazoles useful in treating cardiovascular diseases. |
| US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
| WO2007115966A1 (en) * | 2006-04-11 | 2007-10-18 | F. Hoffmann-La Roche Ag | Heterocyclic gaba alpha subtype selective receptor modulators |
| ITMI20062230A1 (en) * | 2006-11-22 | 2008-05-23 | Acraf | 2-ALCHIL-INDAZOLIC COMPOUND PROCEDURE FOR PREPARATION AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT |
| AR065804A1 (en) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | COMPOSITE OF INDOL CARBOXAMIDE, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND USE OF THIS COMPOUND TO PREPARE A MEDICINAL PRODUCT |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP3239170B1 (en) | 2008-06-04 | 2019-03-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
| WO2012026511A1 (en) * | 2010-08-27 | 2012-03-01 | 協和発酵キリン株式会社 | Pharmaceutical composition |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| SG10202004716RA (en) * | 2014-07-24 | 2020-06-29 | Beta Pharma Inc | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof |
| KR101713303B1 (en) * | 2015-12-24 | 2017-03-07 | 강원대학교산학협력단 | Preparation method of 2H-Indazole derivatives |
| WO2022107064A1 (en) | 2020-11-20 | 2022-05-27 | Idemitsu Kosan Co., Ltd. | Heterocyclic compound and an organic electroluminescence device comprising the heterocyclic compound |
| CN113831319A (en) * | 2021-10-19 | 2021-12-24 | 北京科技大学 | Suzuki reaction method of arylboronic acid/boric acid ester containing large steric hindrance substituent |
| KR20230081778A (en) | 2021-11-29 | 2023-06-08 | 조이운 | VOCs reduction device |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69323212T2 (en) * | 1992-12-17 | 1999-05-27 | Pfizer | PYRAZOLE WITH CRF ANTAGONISTIC ACTIVITY |
| US6005109A (en) * | 1997-10-30 | 1999-12-21 | Pflizer Inc. | Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity |
| FR2701026B1 (en) * | 1993-02-02 | 1995-03-31 | Adir | New derivatives of indole, indazole and benzisoxazole, process for their preparation and pharmaceutical compositions containing them. |
| US5705646A (en) * | 1993-09-30 | 1998-01-06 | Pfizer Inc. | Substituted pyrazoles as CRF antagonists |
| US5668145A (en) * | 1993-11-12 | 1997-09-16 | Pfizer Inc. | Amino-substituted pyrazoles having CRF antagonistic activity |
| US5646152A (en) * | 1994-06-15 | 1997-07-08 | Pfizer Inc. | Methods of administering CRF antagonists |
| US5760225A (en) * | 1996-11-15 | 1998-06-02 | Neurogen Corporation | Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands |
| JP2001521926A (en) | 1997-11-04 | 2001-11-13 | ファイザー・プロダクツ・インク | Indazole bioequivalent replacement of catechol in therapeutically active compounds |
| GB9824310D0 (en) * | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| CA2399791A1 (en) * | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| CA2413002A1 (en) * | 2000-06-30 | 2002-12-19 | Banyu Pharmaceutical Co., Ltd. | Novel pyrazinone derivatives |
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| WO2002016348A1 (en) * | 2000-08-09 | 2002-02-28 | Astrazeneca Ab | Antiangiogenic bicyclic derivatives |
| US20030109550A1 (en) * | 2001-09-19 | 2003-06-12 | Michael Clare | Substituted indazole compounds for the treatment of inflammation |
| FR2836915B1 (en) * | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | AMINOINDAZOLE DERIVATIVES, PREPARATION METHOD AND INTERMEDIATES THEREOF AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME |
| TW200409759A (en) * | 2002-09-25 | 2004-06-16 | Wyeth Corp | Substituted 4-(indazol-3-yl)phenols |
-
2003
- 2003-11-24 BR BR0316950-2A patent/BR0316950A/en not_active IP Right Cessation
- 2003-11-24 ES ES03776916T patent/ES2309368T3/en not_active Expired - Lifetime
- 2003-11-24 MX MXPA05005794A patent/MXPA05005794A/en active IP Right Grant
- 2003-11-24 WO PCT/EP2003/013161 patent/WO2004050634A1/en active IP Right Grant
- 2003-11-24 CA CA002507074A patent/CA2507074A1/en not_active Abandoned
- 2003-11-24 KR KR1020057009878A patent/KR100761562B1/en not_active IP Right Cessation
- 2003-11-24 RU RU2005120770/04A patent/RU2341518C2/en not_active IP Right Cessation
- 2003-11-24 AT AT03776916T patent/ATE399768T1/en not_active IP Right Cessation
- 2003-11-24 PL PL377609A patent/PL377609A1/en not_active Application Discontinuation
- 2003-11-24 EP EP03776916A patent/EP1569911B1/en not_active Expired - Lifetime
- 2003-11-24 CN CNB2003801079699A patent/CN100439341C/en not_active Expired - Fee Related
- 2003-11-24 JP JP2004556171A patent/JP4401298B2/en not_active Expired - Fee Related
- 2003-11-24 DE DE60321958T patent/DE60321958D1/en not_active Expired - Lifetime
- 2003-11-24 AU AU2003286180A patent/AU2003286180B2/en not_active Ceased
- 2003-11-26 TW TW092133163A patent/TW200418816A/en unknown
- 2003-11-27 PA PA20038589601A patent/PA8589601A1/en unknown
- 2003-11-28 UY UY28105A patent/UY28105A1/en not_active Application Discontinuation
- 2003-11-28 PE PE2003001215A patent/PE20040764A1/en not_active Application Discontinuation
- 2003-11-28 GT GT200300263A patent/GT200300263A/en unknown
- 2003-11-28 AR ARP030104398A patent/AR042148A1/en unknown
- 2003-12-01 US US10/724,971 patent/US7214699B2/en not_active Expired - Fee Related
-
2007
- 2007-05-02 US US11/799,605 patent/US20070213373A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW200418816A (en) | 2004-10-01 |
| GT200300263A (en) | 2004-06-28 |
| BR0316950A (en) | 2006-01-17 |
| KR20050084079A (en) | 2005-08-26 |
| US7214699B2 (en) | 2007-05-08 |
| RU2005120770A (en) | 2006-02-10 |
| KR100761562B1 (en) | 2007-10-04 |
| US20070213373A1 (en) | 2007-09-13 |
| JP4401298B2 (en) | 2010-01-20 |
| RU2341518C2 (en) | 2008-12-20 |
| WO2004050634A1 (en) | 2004-06-17 |
| ATE399768T1 (en) | 2008-07-15 |
| CN1732158A (en) | 2006-02-08 |
| EP1569911A1 (en) | 2005-09-07 |
| CA2507074A1 (en) | 2004-06-17 |
| AR042148A1 (en) | 2005-06-08 |
| JP2006510625A (en) | 2006-03-30 |
| MXPA05005794A (en) | 2005-08-16 |
| PA8589601A1 (en) | 2004-09-16 |
| AU2003286180A1 (en) | 2004-06-23 |
| PL377609A1 (en) | 2006-02-06 |
| ES2309368T3 (en) | 2008-12-16 |
| US20040110815A1 (en) | 2004-06-10 |
| DE60321958D1 (en) | 2008-08-14 |
| CN100439341C (en) | 2008-12-03 |
| AU2003286180B2 (en) | 2009-11-12 |
| EP1569911B1 (en) | 2008-07-02 |
| UY28105A1 (en) | 2004-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040764A1 (en) | INDAZOLE DERIVATIVES AS ANTAGONISTS OF CORTICOTROPIN RELEASE FACTOR (CRF) | |
| PE20050308A1 (en) | N-ARYL CARBOXAMIDES HETEROCYCLIC COMPOUNDS AS CYTOKINE INHIBITORS | |
| US8178536B2 (en) | Sirtuin modulating compounds | |
| US8044198B2 (en) | Sirtuin modulating compounds | |
| US8093401B2 (en) | Sirtuin modulating compounds | |
| PE20040946A1 (en) | PYRAZOLOTRIAZINE COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | |
| PE20212069A1 (en) | JAK INHIBITOR COMPOUND AND USE OF JAK | |
| US20070037810A1 (en) | Sirtuin modulating compounds | |
| AR060651A1 (en) | DERIVATIVES OF 1,2,4-TRIAZOL AS MODULATORS OF MGLUR5 I, INTERMEDIARIES FOR SYNTHESIS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF PAIN AND GASTROINTESTINAL DISORDERS | |
| SE0200411D0 (en) | Novel use | |
| ECSP066977A (en) | PGD2 RECEIVER ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
| ATE517908T1 (en) | ANDROSTAN-17-ALPHA-CARBONATE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC AND INFLAMMATORY CONDITIONS | |
| PE97098A1 (en) | DERIVATIVES 6,6- OR 6,7-SUBSTITUTED BICYCLES CONTAINING PIRIDO OR PIRIMIDO | |
| PE20060630A1 (en) | SUBSTITUTE AMIDES OF HAVE-PYRROLCARBOXYLIC ACID, AMIDES OF PYRROLOTIAZOL-CARBOXYL ACID AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE IE | |
| US20030232828A1 (en) | 1-(aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands | |
| CA2218033A1 (en) | Acetamide derivative, process for preparing the same, and a pharmaceutical composition containing the same | |
| PE20051171A1 (en) | PROTEIN INHIBITORS KINASES WITH 3-QUINOLINE CARBONITRILE STRUCTURE | |
| EA200500536A1 (en) | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
| AR038136A1 (en) | CYCLALCANINDOLS WITH REPLACEMENT WITH FLUOR COMPOSITIONS CONTAINING THESE COMPOUNDS AND TREATMENT METHODS | |
| PE20060632A1 (en) | ARYLSULFONYLSTILBENE DERIVATIVES AS ANTAGONISTS OF 5-HT2A RECEPTORS | |
| PE20051095A1 (en) | 1H-HAVE [2,3-c] PIRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS | |
| NI200300053A (en) | USEFUL TROPANO DERIVATIVES IN THERAPY. | |
| PE20170083A1 (en) | NEW COMPOUNDS | |
| AU2009314221B2 (en) | 1-(Arylsulfonyl)-4-(Piperazin-1-yl)-1H-Benzimidazoles as 5-Hydroxytryptamine-6 Ligands | |
| PE20081496A1 (en) | DERIVATIVES OF 2,5-DIHIDRO-3-H-PIRAZOLO [4,3-C] PIRIDAZIN-3-ONA SUBSTITUTED AS ANTAGONISTS OF CB1 RECEPTORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |